Research Reports | Market Assessment
April 2015

Dry Eye | Decision Base | US | 2015

How Receptive Are Ophthalmologists and U.S. Payers to Emerging Therapies in This Underserved Market?

Affecting more than 40 million people in its severe form, dry eye disease represents a large, commercially attractive market that is currently underserved across the major markets in our study, of which only Japan can claim more than one approved prescription drug for the disease. Since the FDA approval of the immunosuppressant cyclosporine ophthalmic emulsion 0.05% (Actavis’s [formerly Allergan’s] Restasis) over a decade ago, no other prescription medicine has been specifically approved for dry eye in the United States, and one prescription drug has been recently approved for dry eye in Europe. Significant opportunity exists for additional therapies that target inflammation as well as other disease pathways characteristic of dry eye.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports